NCT04088864View on ClinicalTrials.gov

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

October 31, 2023

Study Completion Date

September 10, 2036

Conditions
B Cell LymphomaAcute Lymphoblastic Leukemia, PediatricLymphoma
Interventions
DRUG

Fludarabine

Fludarabine is a purine antagonist antimetabolite

DRUG

Cyclophosphamide

Cyclophosphamide is a nitrogen mustard derivative alkylating agent

DRUG

Autologous CD22 CAR T

Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)

Trial Locations (1)

94304

Stanford Medical Center, Stanford

All Listed Sponsors
lead

Stanford University

OTHER